Croatian Firm Pliva To Be Privatized

4 March 1996

The Croatian government is to privatize its largest drug company, Pliva, as part of a more general state program of privatization. 30% of the shares are to be offered to foreign investors worldwide. The current stakeholders are the state privatization fund, the CPF, with 52.02%, the state pension fund for industrial workers with 21.99%, the agricultural workers' pension fund with 9.43%, and smaller shareholders hold the remaining shares.

Following completion of the share offer, it is understood that the European Bank for Reconstruction and Development will acquire new shares to the value of nearly $42 million so that over half Pliva's share capital will then be in private hands. The shares will be listed in London and Zagreb, and the offer will be coordinated by Schweizerissche Bankgesellschaft and Zagrebaca Banka. The operation is expected to be completed in the first six months of the current year.

Pliva posted sales of around $375 million for 1995, with pretax profits of some $85 million. Human pharmaceuticals accounted for around 71% of total sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight